Ascendis Pharma to Participate in the Oppenheimer 33rd Annual Healthcare Conference
10 mars 2023 08h00 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, March 10, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive...
Ascendis Pharma Reports Full Year 2022 Results
16 févr. 2023 16h01 HE
|
Ascendis Pharma
TransCon™ PTH PDUFA date of April 30, 2023, for adults with hypoparathyroidism; European MAA decision expected in the fourth quarter of 2023Expanding TransCon hGH geographic reach with planned launch...
Ascendis Pharma Announces Full Year 2022 Financial Results and Business Update Conference Call on February 16
07 févr. 2023 08h00 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the company will hold a conference call and live webcast on Thursday, February 16,...
Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Morgan Healthcare Conference
08 janv. 2023 17h00 HE
|
Ascendis Pharma
– On track to fulfill all elements of Vision 3x3 to build a sustainable, profitable, leading biopharma company COPENHAGEN, Denmark, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:...
Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma’s TransCon™ PTH for Eligible U.S. Adult Patients with Hypoparathyroidism
04 janv. 2023 08h00 HE
|
Ascendis Pharma
- The Expanded Access Program (EAP) allows physicians to request access to TransCon PTH, the company’s investigational parathyroid hormone replacement therapy, for eligible patients in the United...
Ascendis Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 08h00 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the Company is scheduled to present at the 41st Annual J.P. Morgan Healthcare...
Ascendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult Patients with Hypoparathyroidism
05 déc. 2022 08h00 HE
|
Ascendis Pharma
- The program will allow physicians to request access to TransCon PTH, the company’s investigational parathyroid hormone replacement therapy, for eligible patients in the United States - TransCon...
Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference
22 nov. 2022 08h30 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to participate in the 5th Annual Evercore ISI HealthCONx...
Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ PTH in Adult Patients with Hypoparathyroidism
14 nov. 2022 07h00 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines...
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years
13 nov. 2022 18h15 HE
|
Ascendis Pharma
- Data demonstrated that once-weekly TransCon CNP has the potential to meet patient and caregiver needs for a safe, effective, tolerable and convenient treatment - The primary endpoint,...